inactive wee1 protein Search Results


inactive wee1 protein  (Novus Biologicals)
93
Novus Biologicals inactive wee1 protein
a , Representative western blot analysis in KAP 2D cells upon 1 day of treatment with 1 µM SKL, BIRB-796, 1639, 2015 or DMSO (cropped blot images; n = 3 biologically independent experiments). b , Representative western blot analysis for <t>p38α–Wee1</t> kinase assay (cropped blot images; n = 3 independent kinase assays). c , Representative western blot analysis in KAP 2D cells upon 1 day of treatment with 1 µM SKL, BIRB-796, 1639, 2015 or DMSO (cropped blot images; n = 3 biologically independent experiments). d – f , Quantification ( d ), representative pictures ( e ) and determination of mitotic phases ( f ) of KAP 2D cells stained for P-H3 S10 and α-tubulin after 1 day of treatment with 1 µM, SKL, 1639, 2015 or DMSO ( n = 3 cultures per condition; data are presented as the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.001). Scale bars, 100 µm. g , h , Representative confocal microscopy pictures of stained KAP 2D ( g ) and PDO5 ( h ) after 1 day of treatment with 1 µM 2015 or DMSO ( n = 3 cultures per condition). Scale bars, 15 µm. i , Quantification of viable KAP 2D upon treatment with 1 µM SKL, 1639, 2015 or DMSO ( n = 3 cultures per condition; data are presented as the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.0001). j , k , Quantification ( j ) and representative pictures ( k ) of EdU-labeled KAP 2D after 2 days of treatment with 1 µM SKL, 1639, 2015 or DMSO ( n = 4 cultures per condition; values represent the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.0001). Scale bars, 50 µm. l , Representative size analysis of KAP 2D upon 2 days of treatment with 1 µM SKL, 1639, 2015 or DMSO (measurements without gating; n = 3 cultures per condition). m , Representative DNA content analysis in KAP 2D upon 1 day of treatment with 1 µM SKL, 1639, 2015 or DMSO (gating strategy in Extended Data Fig. ; n = 3 cultures per condition). The experiments in a – c were independently performed three times and the experiments in d – m were independently performed twice, all with similar results.
Inactive Wee1 Protein, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inactive+wee1+protein/pmc11864979-388-22-25?v=Novus+Biologicals
Average 93 stars, based on 1 article reviews
inactive wee1 protein - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
anti p cdk1 thr161  (St Johns Laboratory)
93
St Johns Laboratory anti p cdk1 thr161
a , Representative western blot analysis in KAP 2D cells upon 1 day of treatment with 1 µM SKL, BIRB-796, 1639, 2015 or DMSO (cropped blot images; n = 3 biologically independent experiments). b , Representative western blot analysis for <t>p38α–Wee1</t> kinase assay (cropped blot images; n = 3 independent kinase assays). c , Representative western blot analysis in KAP 2D cells upon 1 day of treatment with 1 µM SKL, BIRB-796, 1639, 2015 or DMSO (cropped blot images; n = 3 biologically independent experiments). d – f , Quantification ( d ), representative pictures ( e ) and determination of mitotic phases ( f ) of KAP 2D cells stained for P-H3 S10 and α-tubulin after 1 day of treatment with 1 µM, SKL, 1639, 2015 or DMSO ( n = 3 cultures per condition; data are presented as the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.001). Scale bars, 100 µm. g , h , Representative confocal microscopy pictures of stained KAP 2D ( g ) and PDO5 ( h ) after 1 day of treatment with 1 µM 2015 or DMSO ( n = 3 cultures per condition). Scale bars, 15 µm. i , Quantification of viable KAP 2D upon treatment with 1 µM SKL, 1639, 2015 or DMSO ( n = 3 cultures per condition; data are presented as the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.0001). j , k , Quantification ( j ) and representative pictures ( k ) of EdU-labeled KAP 2D after 2 days of treatment with 1 µM SKL, 1639, 2015 or DMSO ( n = 4 cultures per condition; values represent the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.0001). Scale bars, 50 µm. l , Representative size analysis of KAP 2D upon 2 days of treatment with 1 µM SKL, 1639, 2015 or DMSO (measurements without gating; n = 3 cultures per condition). m , Representative DNA content analysis in KAP 2D upon 1 day of treatment with 1 µM SKL, 1639, 2015 or DMSO (gating strategy in Extended Data Fig. ; n = 3 cultures per condition). The experiments in a – c were independently performed three times and the experiments in d – m were independently performed twice, all with similar results.
Anti P Cdk1 Thr161, supplied by St Johns Laboratory, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/inactive+wee1+protein/pmc12055519-49-0-8?v=St+Johns+Laboratory
Average 93 stars, based on 1 article reviews
anti p cdk1 thr161 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


a , Representative western blot analysis in KAP 2D cells upon 1 day of treatment with 1 µM SKL, BIRB-796, 1639, 2015 or DMSO (cropped blot images; n = 3 biologically independent experiments). b , Representative western blot analysis for p38α–Wee1 kinase assay (cropped blot images; n = 3 independent kinase assays). c , Representative western blot analysis in KAP 2D cells upon 1 day of treatment with 1 µM SKL, BIRB-796, 1639, 2015 or DMSO (cropped blot images; n = 3 biologically independent experiments). d – f , Quantification ( d ), representative pictures ( e ) and determination of mitotic phases ( f ) of KAP 2D cells stained for P-H3 S10 and α-tubulin after 1 day of treatment with 1 µM, SKL, 1639, 2015 or DMSO ( n = 3 cultures per condition; data are presented as the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.001). Scale bars, 100 µm. g , h , Representative confocal microscopy pictures of stained KAP 2D ( g ) and PDO5 ( h ) after 1 day of treatment with 1 µM 2015 or DMSO ( n = 3 cultures per condition). Scale bars, 15 µm. i , Quantification of viable KAP 2D upon treatment with 1 µM SKL, 1639, 2015 or DMSO ( n = 3 cultures per condition; data are presented as the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.0001). j , k , Quantification ( j ) and representative pictures ( k ) of EdU-labeled KAP 2D after 2 days of treatment with 1 µM SKL, 1639, 2015 or DMSO ( n = 4 cultures per condition; values represent the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.0001). Scale bars, 50 µm. l , Representative size analysis of KAP 2D upon 2 days of treatment with 1 µM SKL, 1639, 2015 or DMSO (measurements without gating; n = 3 cultures per condition). m , Representative DNA content analysis in KAP 2D upon 1 day of treatment with 1 µM SKL, 1639, 2015 or DMSO (gating strategy in Extended Data Fig. ; n = 3 cultures per condition). The experiments in a – c were independently performed three times and the experiments in d – m were independently performed twice, all with similar results.

Journal: Nature Cancer

Article Title: First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer

doi: 10.1038/s43018-024-00899-7

Figure Lengend Snippet: a , Representative western blot analysis in KAP 2D cells upon 1 day of treatment with 1 µM SKL, BIRB-796, 1639, 2015 or DMSO (cropped blot images; n = 3 biologically independent experiments). b , Representative western blot analysis for p38α–Wee1 kinase assay (cropped blot images; n = 3 independent kinase assays). c , Representative western blot analysis in KAP 2D cells upon 1 day of treatment with 1 µM SKL, BIRB-796, 1639, 2015 or DMSO (cropped blot images; n = 3 biologically independent experiments). d – f , Quantification ( d ), representative pictures ( e ) and determination of mitotic phases ( f ) of KAP 2D cells stained for P-H3 S10 and α-tubulin after 1 day of treatment with 1 µM, SKL, 1639, 2015 or DMSO ( n = 3 cultures per condition; data are presented as the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.001). Scale bars, 100 µm. g , h , Representative confocal microscopy pictures of stained KAP 2D ( g ) and PDO5 ( h ) after 1 day of treatment with 1 µM 2015 or DMSO ( n = 3 cultures per condition). Scale bars, 15 µm. i , Quantification of viable KAP 2D upon treatment with 1 µM SKL, 1639, 2015 or DMSO ( n = 3 cultures per condition; data are presented as the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.0001). j , k , Quantification ( j ) and representative pictures ( k ) of EdU-labeled KAP 2D after 2 days of treatment with 1 µM SKL, 1639, 2015 or DMSO ( n = 4 cultures per condition; values represent the mean ± s.d.). Statistical significance was calculated using an ANOVA and Tukey’s multiple-comparisons test ( P < 0.0001). Scale bars, 50 µm. l , Representative size analysis of KAP 2D upon 2 days of treatment with 1 µM SKL, 1639, 2015 or DMSO (measurements without gating; n = 3 cultures per condition). m , Representative DNA content analysis in KAP 2D upon 1 day of treatment with 1 µM SKL, 1639, 2015 or DMSO (gating strategy in Extended Data Fig. ; n = 3 cultures per condition). The experiments in a – c were independently performed three times and the experiments in d – m were independently performed twice, all with similar results.

Article Snippet: The Wee1 kinase assay was performed with recombinant human active p38α protein (Abcam, ab271647), mostly inactive MK2 protein (Abcam, ab79910) and mostly inactive Wee1 protein (Novus Biologicals, H00007465-P01).

Techniques: Western Blot, Kinase Assay, Staining, Confocal Microscopy, Labeling